General Announcement::Glenmark Pharmaceuticals announces product approval for Ryaltris in Australia

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
20-Dec-2019 13:18:03
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals announces product approval for Ryaltris in Australia
Announcement Reference
SG191220OTHRBFJ5
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
20/12/2019 10:44:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Pharmaceuticals announces product approval for Ryaltris in Australia

Attachments

SGX_PR_20.12.2019.pdf
Total size =533K